Ibrutinib Restores Tumor-specific Adaptive Immunity in Chronic Lymphocytic Leukemia.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Chronic lymphocytic leukemia (CLL) is characterized by early and profound immune suppression and reversal of these effects is essential to improve patient outcome. Targeted therapy with small-molecule inhibitors such as ibrutinib is highly effective and tolerable. Emerging data suggest that patients with CLL responding to ibrutinib therapy can recover anti-CLL adaptive immune cytotoxicity.See related article by Baptista et al., p. 4624.

Keyphrases

chronic lymphocytic leukemia
small molecule
case report
electronic health record
intellectual disability
big data
protein protein
deep learning